Drugging Cancers Big Four
What does it mean to drug cancer’s “big four”? Learn how Darryl McConnell & his team are tackling one of the biggest scientific conundrums.
Search
Supply Chain Scholarship for Cowtribe
A supply chain course we sponsored boosted the career of Latifa Saaka
Boehringer Ingelheim puts patient needs first as reflected in the results of the latest “PatientView”
Boehringer Ingelheim puts patient needs first as reflected in the results of the latest “PatientView” survey
Boehringer Ingelheim Brings Hundreds of Leading Cardiologists from Eight Countries Together
Boehringer Ingelheim Brings Hundreds of Leading Cardiologists from Eight Countries Together
Boehringer Ingelheim Opens New Scientific Office in Kenya as Part of its Commitment to Improve Human and Animal Health in Africa
Boehringer Ingelheim has officially opened its new scientific office in Nairobi, Kenya.
The little things
In 2009 Anna was diagnosed with scleroderma. For her, however, the disease is no reason to give up. On the contrary.
On two wheels for more animal health
Cowtribe’s social entrepreneurs win Boehringer Ingelheim's Accelerator Program.
When profitability is just a consequence
Learn how reproductive technologies and animal welfare ensure cows produce more milk, live better and have shorter calving intervals
Big hearts united to help animals in Ukraine
Veterinaries volunteer at the Polish-Ukrainian border to help welcome Refugees and their animals. Refugees don’t rest until their animals are safe.
Lead with Pride – for the Benefit of All.
How Inclusive Leadership advocates for Acceptance and creating a Sense of Belonging
German Ambassador inaugurates Boehringer Ingelheim new Cairo office
German Ambassador inaugurates Boehringer Ingelheim new Cairo office
Boehringer Ingelheim Launches New Arabic Website to Support Patients Living with Idiopathic
Boehringer Ingelheim Launches New Arabic Website to Support Patients Living with Idiopathic Pulmonary Fibrosis in the Region
Three challenges shape future antiparasitic treatment
The three key challenges that will shape the future of antiparasitic treatment
New approaches in the battle against heartworm disease
Heartworm disease is a concern to dog and cat owners worldwide. Current disease control methods are increasingly challenged by drug resistance. We explore the potential for novel treatments and vaccines based on new knowledge and technology.
KidZania, Purina, & Boehringer Ingelheim Promote Veterinary Career Paths & Pet Health in Dubai
KidZania, Purina, & Boehringer Ingelheim Promote Veterinary Career Paths & Pet Health in Dubai
“Rapid progress towards clinical candidates”
Boehringer Ingelheim forms a joint venture to create the next generation of antimicrobials.
Boehringer Ingelheim collaborates with local universities in Nairobi, Kenya to introduce
Boehringer Ingelheim collaborates with local universities in Nairobi, Kenya to introduce development program for young professionals
The beginning of the end for KRAS cancers
Learn how Darryl McConnell & his team are tackling the “the beating heart of cancer”
Boehringer Ingelheim inaugurates new milestone on its long-term commitment to the Kingdom
Boehringer Ingelheim inaugurates new milestone on its long-term commitment to the Kingdom
Regional experts highlight need for coordinated, collaborative efforts in stroke care through
Regional experts highlight need for coordinated, collaborative efforts in stroke care through dedicated hospital unitsRegional experts highlight need for coordinated, collaborative efforts in stroke care through dedicated hospital units
View from Both Sides of the Table
Scott DeWire, US Head of BD&L shares experiences that have taught him first-hand the foundations of successful partnerships
Boehringer Ingelheim Builds on 100 Years of Expertise To Continue Raising Awareness of Respiratory
Boehringer Ingelheim Builds on 100 Years of Expertise To Continue Raising Awareness of Respiratory Diseases
1885-1948: Innovative beginnings
The Boehringer Ingelheim history from its start in 1885 to 1948, with milestones and important products
1990-2022: Value through Innovation
The Boehringer Ingelheim history from 1990 to 2022, with milestones
The UAE MOHAP Approves the First and Only Therapy for the Treatment of Adult Generalized Pustular Psoriasis Flares
The first treatment of its kind in the UAE by Boehringer Ingelheim is the only FDA and EMA-approved medication used to treat GPP flares in adult patients and works to help block a source of inflammation that may cause GPP flares